EA201170300A1 - Кристаллические формы пиридинового производного - Google Patents

Кристаллические формы пиридинового производного

Info

Publication number
EA201170300A1
EA201170300A1 EA201170300A EA201170300A EA201170300A1 EA 201170300 A1 EA201170300 A1 EA 201170300A1 EA 201170300 A EA201170300 A EA 201170300A EA 201170300 A EA201170300 A EA 201170300A EA 201170300 A1 EA201170300 A1 EA 201170300A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystal forms
pyridine derivative
solvate
therapy
compound
Prior art date
Application number
EA201170300A
Other languages
English (en)
Russian (ru)
Inventor
Клер Луиз Андертон
Дэвид Клапхэм
Ронни Максвелл Лоуренс
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201170300A1 publication Critical patent/EA201170300A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201170300A 2008-08-05 2009-08-04 Кристаллические формы пиридинового производного EA201170300A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
EA201170300A1 true EA201170300A1 (ru) 2011-08-30

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170300A EA201170300A1 (ru) 2008-08-05 2009-08-04 Кристаллические формы пиридинового производного

Country Status (14)

Country Link
US (1) US8093242B2 (cg-RX-API-DMAC10.html)
EP (1) EP2321324A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011529942A (cg-RX-API-DMAC10.html)
KR (1) KR20110052686A (cg-RX-API-DMAC10.html)
CN (1) CN102171219A (cg-RX-API-DMAC10.html)
AU (1) AU2009279135B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0917224A2 (cg-RX-API-DMAC10.html)
CA (1) CA2733235A1 (cg-RX-API-DMAC10.html)
EA (1) EA201170300A1 (cg-RX-API-DMAC10.html)
GB (1) GB0814340D0 (cg-RX-API-DMAC10.html)
IL (1) IL210777A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011001414A (cg-RX-API-DMAC10.html)
WO (1) WO2010015626A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201100426B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP4058433A1 (en) * 2019-11-15 2022-09-21 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912174B1 (en) 1996-07-17 2004-04-28 MERCK & CO., INC. Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
AU7788500A (en) 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ES2291891T3 (es) * 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
DK1928886T3 (da) * 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser

Also Published As

Publication number Publication date
MX2011001414A (es) 2011-04-04
US8093242B2 (en) 2012-01-10
CN102171219A (zh) 2011-08-31
EP2321324A1 (en) 2011-05-18
AU2009279135B2 (en) 2012-09-13
AU2009279135A1 (en) 2010-02-11
GB0814340D0 (en) 2008-09-10
KR20110052686A (ko) 2011-05-18
ZA201100426B (en) 2012-03-28
US20110136798A1 (en) 2011-06-09
CA2733235A1 (en) 2010-02-11
BRPI0917224A2 (pt) 2015-11-24
IL210777A0 (en) 2011-03-31
WO2010015626A1 (en) 2010-02-11
JP2011529942A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
EA201270302A1 (ru) Безводные формы производных пиридина
EA201100030A1 (ru) Пиразольные соединения 436
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
BRPI0916735B8 (pt) compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
EA201170772A1 (ru) Органические соединения
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
EA201001769A1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201492005A1 (ru) Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
BR112014018702A8 (pt) Composto, cristal, inibidor, medicamento, composição farmacêutica, e, uso de um composto ou sal
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
NO20090628L (no) Pyridizinon derivativater
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
EA201390381A1 (ru) Триазиноксадиазолы
UA111770C2 (uk) Інгібітори бромдомену
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение